NRXP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 02:47):

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases...

Stats
今日成交量	208 194
平均成交量	250 477
市值	21.22M
EPS	US089482100 ( 2024-03-28 )
下一个收益日期	( US089482100 ) 2024-05-14
Last Dividend	US089482100 ( N/A )
Next Dividend	US089482100 ( N/A )
P/E	-0.500
ATR14	US089482100.0190 (0.95%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-28	Rehnquist Janet	Buy	0
2023-09-13	Narido Richard Clavano	Buy	0
2023-08-30	Gorovitz Aaron	Buy	35 000	Common Stock, par value $0.001 per share
2023-08-30	Hurvitz Chaim	Buy	70 000	Common Stock, par value $0.001 per share
2023-08-23	Javitt Jonathan C	Buy	100 000	Common Stock

INSIDER POWER
3.37
Last 86 transactions
Buy: 35 919 718 \| Sell: 5 833 033

音量相关性

長: -0.09 (neutral)

短: 0.25 (neutral)

Signal:(52.135) Neutral

NRx Pharmaceuticals, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

NRx Pharmaceuticals, Inc. 相关性 - 货币/商品

-0.73
( moderate negative )

-0.74
( moderate negative )

0.00
( neutral )

-0.58
( weak negative )

-0.49
( neutral )

0.69
( moderate )

NRx Pharmaceuticals, Inc. 财务报表

Annual	2023
营收:	US089482100
毛利润:	US08948210-5 000.00 (0.00 %)
EPS:	US08948210-3.98

FY	2023
营收:	US089482100
毛利润:	US08948210-5 000.00 (0.00 %)
EPS:	US08948210-3.98

FY	2022
营收:	US089482100
毛利润:	US08948210-4 000.00 (0.00 %)
EPS:	US08948210-0.540

FY	2021
营收:	US089482100.00
毛利润:	US089482100.00 (0.00 %)
EPS:	US08948210-7.44

Financial Reports:

No articles found.

NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.